• Username (E-mail)
  • Password
Dow 19,800 -0.1%  EStoxx50 3,281 0.3%  Nikkei 18,788 -0.6%  EUR 1.0731 -0.3% 
Nasdaq 5,553 0.0%  FTSE100 7,172 0.3%  Yen 113.3740 0.7%  Oil 55.5 0.2% 
S&P500 2,265 -0.3%  DAX 11,575 0.3%  GBP 1.2448 -0.7%  Gold 1,212 -0.6% 

Regeneron Pharmaceuticals share [Symbol: REGN / ISIN: US75886F1075]

Realtimequote Regeneron Pharmaceuticals Inc. in USD

Exchange Market
354.22
Last
0
Volume
Time 03:59 PM
01/23/2017 03:59:52 PM UTC-0500
activate push

Stock Price Regeneron Pharmaceuticals Inc. in USD

Activate push
354.36 USD -8.20 USD -2.26 %
Trade Time 8:10 PM Trade Date 1/23/2017
Daily High 0.00 Open 0.00
Daily Low 0.00 Prev. Close 362.56
52-week High 482.27 Volume (Qty.) 0
52-week Low 325.62 Market Cap (USD) 37.97 B
52-week Perf.
Exchange

Analyst Opinions for Regeneron Pharmaceuticals Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
11/20/12
Regeneron Pharmaceuticals RBC Capital Markets
08/29/12
Regeneron Pharmaceuticals RBC Capital Markets
08/22/12
Regeneron Pharmaceuticals RBC Capital Markets
07/27/12
Regeneron Pharmaceuticals RBC Capital Markets
07/25/12
Regeneron Pharmaceuticals RBC Capital Markets

Moody's Rating for Regeneron Pharmaceuticals Inc.

Investment Grade (High Grade)
Investment Grade (Medium Grade)
Speculative Grade
Rating
Rating Update
Date of Rating
Rating Office -

Profile Regeneron Pharmaceuticals Inc.

Company Profile
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma and atopic dermatitis. Its products include EYLEA (aflibercept) injection, which is used for the treatment of neovascular age related macular degeneration; ARCALYST (rilonacept), which is used for the treatment of Cryopyrin-Associated Periodic Syndrome, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome; and PRALUENT (alirocumab) Injection for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL- C. Regeneron Pharmaceuticals was founded by Alferd G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
pagehit

Add or Edit Instrument

Regeneron Pharmaceuticals Chart - 1 Year - NAS
  • Intraday
  • 1w
  • 3 Mo.
  • 1y
  • 3y
  • 5y
  • Max
  • Exchange: NAS
  • Chart Options

Estimates for Regeneron Pharmaceuticals

2015 2016e 2017e
Dividend - - -
Dividend Yield in % - - -
P/E Ratio 44.97 33.98 26.94
EPS 12.07 11.62 14.66

Regeneron Pharmaceuticals Key Figures

Market Cap (USD) 37.97 B
Free Float in % 74.71
Number of Shares (Mio.) 103.56
Cash Flow per Share 5.11
Book Value per Share 35.28
60-Days Volatility 44.81
P/B Ratio 15.39

Base Data Regeneron Pharmaceuticals

Symbol REGN
ISIN US75886F1075
Indices NASDAQ Comp., S&P 500, NASDAQ 100, BX Swiss - USA

About the Company Regeneron Pharmaceuticals

Country USA

Regeneron Pharmaceuticals Historical Prices

01/19/2017
01/19/2017 06:00:00 PM UTC-0500
362.56 298,597
01/18/2017
01/18/2017 06:00:00 PM UTC-0500
363.41 174,377
01/17/2017
01/17/2017 06:00:00 PM UTC-0500
362.95 185,811
01/16/2017
01/16/2017 06:00:00 PM UTC-0500
363.24 224,041
01/12/2017
01/12/2017 06:00:00 PM UTC-0500
368.16 296,992

Regeneron Pharmaceuticals Peer Group

Similar shares with higher 1-year perf.